OM:BIOA BBiotechs
How Strong Lecanemab Persistence Data At BioArctic (OM:BIOA B) Has Changed Its Investment Story
In March 2026, BioArctic and its partner Eisai presented new real-world and scientific data on Alzheimer’s drug lecanemab and BioArctic’s Parkinson’s research at the AD/PD Conference in Copenhagen, highlighting treatment persistence and mechanistic insights.
The high proportion of early Alzheimer’s patients staying on lecanemab beyond 18 months, alongside BioArctic’s ongoing R&D presentations, underscores the company’s role in shaping emerging standards of care in neurodegenerative...